LBP-EC01 is a bacteriophage ‘cocktail’ that has been modified using CRISPR/Cas3 gene-editing to improve its ability to target the E coli genome. Lab studies have demonstrated it is ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.